Ruboxistaurin

From Wikipedia, the free encyclopedia

Ruboxistaurin
Systematic (IUPAC) name
13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione
Identifiers
CAS number 169939-94-0
ATC code  ?
PubChem 153999
Chemical data
Formula C28H28N4O3 
Mol. mass 468.546 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy. It is currently being investigated by Lilly.

On February, 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.[2]

[edit] References

  1. ^ Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant. Retrieved on 2008-02-15.
  2. ^ Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy. Retrieved on 2008-02-15.

[edit] External links

Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.